This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
Biktarvy
From Proteopedia
(Difference between revisions)
(New page: <StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='98/989308/Cv/1'> Bictegravir/emtricitabine/tenofovir alafenamide, sold under the brand...) |
|||
| Line 1: | Line 1: | ||
<StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='98/989308/Cv/1'> | <StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='98/989308/Cv/1'> | ||
| - | [[Bictegravir]]/[[emtricitabine]]/tenofovir alafenamide, sold under the brand name Biktarvy, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS. One tablet, taken orally once daily, contains 50 mg bictegravir, 200 mg emtricitabine, and 25 mg tenofovir alafenamide.[ | + | [[Bictegravir]]/[[emtricitabine]]/tenofovir alafenamide, sold under the brand name Biktarvy, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS. One tablet, taken orally once daily, contains 50 mg bictegravir, 200 mg emtricitabine, and 25 mg tenofovir alafenamide.<ref name="a4">[https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=664cb8f0-1f65-441b-b0d9-ba3d798be309 "Biktarvy- bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate tablet".] DailyMed. 8 August 2019. Retrieved 7 March 2020.</ref> It was approved for use in the United States in February 2018,<ref name="a5">[https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210251Orig1s000TOC.cfm "Drug Approval Package: Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) Tablets".] U.S. Food and Drug Administration (FDA). 19 March 2018. Retrieved 7 March 2020.</ref><ref name="a6">[https://www.businesswire.com/news/home/20180207006071/en/U.S.-Food-Drug-Administration-Approves-Gilead%E2%80%99s-Biktarvy%C2%AE "U.S. Food and Drug Administration Approves Gilead's Biktarvy (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV-1 Infection"] (Press release). Gilead. 7 February 2018.</ref> and for use in the European Union in June 2018.<ref name="a7">[https://www.ema.europa.eu/en/medicines/human/EPAR/biktarvy "Biktarvy EPAR".] European Medicines Agency (EMA). 21 January 2020. Retrieved 7 March 2020.</ref> |
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||
Revision as of 12:43, 29 August 2023
| |||||||||||
References
- ↑ "Biktarvy- bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate tablet". DailyMed. 8 August 2019. Retrieved 7 March 2020.
- ↑ "Drug Approval Package: Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) Tablets". U.S. Food and Drug Administration (FDA). 19 March 2018. Retrieved 7 March 2020.
- ↑ "U.S. Food and Drug Administration Approves Gilead's Biktarvy (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV-1 Infection" (Press release). Gilead. 7 February 2018.
- ↑ "Biktarvy EPAR". European Medicines Agency (EMA). 21 January 2020. Retrieved 7 March 2020.
